Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.

Intellia (NTLA) Focuses on Developing Gene-Editing Therapies

CRISPR Therapeutics

Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time

Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.

Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance

The FDA gave Intellia the go-ahead to begin a pivotal study of its gene-editing treatment for a heart disease, but NTLA stock fell.

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy. The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is expected to initiate by year-end 2023.

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.

Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation

Gene-editing stocks have gotten pummeled by the market's growing aversion to risk. Nonetheless, the field has made substantial progress of late.

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Palantir Technologies

Growth stocks have been on a wild ride since the start of 2022. Despite this marked volatility, some growth stocks still come across as outstanding buys for patient investors.

2 Brilliant Growth Stocks to Buy and Hold Forever

Intellia has declined over the past year even as its candidates for severe diseases have advanced in clinical studies. The company aims to launch a phase 3 trial for one of its candidates as early as next year.

Down 45%, Is Intellia a Buy?

Intellia's leading candidates look promising, but there's a long way to go before they hit the market. If the company can deliver regular clinical and regulatory wins, its stock could provide outsized returns.

This Cathie Wood Stock Is Poised to Double, Says Wall Street

Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.

Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies

Intellia Therapeutics has a pair of promising gene-editing therapies in the works. It also has a highly technically advanced program that could enter trials soon.

Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases, the companies said on Tuesday.

Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies

Intellia Therapeutics' high R&D expenses drive $132.3M operating loss but robust liquidity and 27-month cash runway offer financial cushion. NTLA-2002 for HAE shows transformative Phase 1 results, becoming a key asset despite mixed market sentiment and institutional caution. Investment Recommendation: Downgraded to "Buy" from "Strong Buy," due to OpEx concerns and market sentiment, despite promising HAE program.

Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects

Wisdomtree BioRevolution Fund

The healthcare sector is disappointing this year. And the ICE Biotechnology Index is even more of a dud on a year-to-date basis.

Multiple Reasons to Bet on Biotech ETF WDNA

Biogen

bluebird bio

BioMarin Pharmaceutical

Editas Medicine

Novartis

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Rocket Pharma

Rocket Pharmaceuticals has two programs approaching commercialization. By contrast, Intellia's candidates won't be ready for quite some time.

Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals

Gilead Sciences

Many gene-editing biotechs are developing cures. Curing patients is good.

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know

Advanced Micro Devices

Medtronic

Moderna

NVIDIA

Vertex Pharmaceuticals

Before investing in a trend, it's important to make sure it isn't a fad of the moment and instead has staying power. Artificial intelligence and CRISPR gene editing are two popular trends that could be game-changers down the road.

2 Top Trends to Invest $500 In Right Now

Ginkgo Bioworks Holdings

Cathie Wood likes to buy innovative and disruptive companies. She's been buying both Intellia Therapeutics and Ginkgo Bioworks recently.

Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double

Cathie Wood has been buying shares of Intellia since December -- but she recently increased the pace of those transactions. Intellia could become a leader in the innovative field of gene editing.

Cathie Wood Is Buying This Stock Hand Over Fist. Should You?

AbbVie

Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority voters. This commitment to economic inclusivity bodes well for overall economic health and long-term growth.

The 3 Most Promising Biotech Stocks to Own Now

Accolade

Invitae

Recursion Pharmaceuticals

Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.

Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

News for Intellia Therapeutics Stock (NTLA)